BioSpace News Archive

Sosei Group Corporation has announced it is regaining the worldwide rights to its muscarinic agonist programs after AbbVie said it is backing away from the program.

2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.

Micron Medical, a privately-held medical device company engaged in the development, manufacture and early stage commercialization of innovative wireless, minimally invasive, electroceutical solutions for urological conditions, focused on OAB, announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Intercept Pharmaceuticals, Inc. announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference

Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced it has dosed the first patient in a Phase 1, open-label, dose-escalation and expansion clinical trial of RP3 both alone and in combination with anti-PD-1 therapy.

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., chief executive officer will virtually present at the 39th Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference

Endo International plc announced that its subsidiary, Endo Aesthetics LLC, launched an unbranded campaign designed to eliminate the shame and misinformation relating to cellulite.